MLN0128, a Second-Generation mTOR Kinase Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML

被引：0
|
作者：
Zeng, Zhihong [1 ]
Wang, Rui-Yu [1 ]
Shi, Yuexi [1 ]
Qiu, Yihua [1 ]
Mak, Duncan H. [2 ]
Coombes, Kevin [3 ]
Yoo, Suk Young [1 ]
Jessen, Katti [4 ]
Liu, Yi [5 ]
Rommel, Christian [6 ]
Kantarjian, Hagop M. [1 ]
Kornblau, Steven M. [1 ]
Fruman, David [7 ]
Andreeff, Michael [1 ]
Konopleva, Marina [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Sect Mol Hematol & Therapy, Houston, TX 77030 USA
[3] Ohio State Univ, Columbus, OH 43210 USA
[4] eFFECTOR Therapeut, San Diego, CA USA
[5] Wellspring Biosci, San Diego, CA USA
[6] 5Amgen Inc, Thousand Oaks, CA USA
[7] UC Irvine, Irvine, CA USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 20 条
  • [1] MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells
    Zeng, Zhihong
    Wang, Rui-Yu
    Qiu, Yi Hua
    Mak, Duncan H.
    Coombes, Kevin
    Yoo, Suk Young
    Zhang, Qi
    Jessen, Katti
    Liu, Yi
    Rommel, Christian
    Fruman, David A.
    Kantarjian, Hagop M.
    Kornblau, Steven M.
    Andreeff, Michael
    Konopleva, Marina
    ONCOTARGET, 2016, 7 (34) : 55083 - 55097
  • [2] Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program
    Kang, Min H.
    Reynolds, C. Patrick
    Maris, John M.
    Gorlick, Richard
    Kolb, E. Anders
    Lock, Richard
    Carol, Hernan
    Keir, Stephen T.
    Wu, Jianrong
    Lyalin, Dmitry
    Kurmasheva, Raushan T.
    Houghton, Peter J.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (08) : 1486 - 1489
  • [3] THE NOVEL BRUTON'S TYROSINE KINASE INHIBITOR ARQ531, DISRUPTS SURVIVAL SIGNALING AND TRIGGERS APOPTOSIS IN AML CELLS
    Soncini, D.
    Minetto, P.
    Ruberti, S.
    Retali, V.
    Orecchioni, S.
    Contini, P.
    Cagnetta, A.
    Eathiraj, S.
    Abbadessa, G.
    Schwartz, B.
    Nencioni, A.
    Todoerti, K.
    Agnelli, L.
    Bertolini, F.
    Neri, A.
    Gobbi, M.
    Lemoli, R. M.
    Cea, M.
    HAEMATOLOGICA, 2018, 103 : S71 - S71
  • [4] The novel Bruton's tyrosine kinase inhibitor ARQ531 disrupts survival signaling and triggers apoptosis in AML cells
    Debora, Soncini
    Orecchioni, Stefania
    Cagnetta, Antonia
    Retali, Veronica
    Ruberti, Samantha
    Minetto, Paola
    Contini, Paola
    Nencioni, Alessio
    Monacelli, Fiammetta
    Hall, Terence
    Gobbi, Marco
    Eathiraj, Sudharshan
    Schwartz, Briam
    Bertolini, Francesco
    Lemoli, Roberto
    Cea, Michele
    CANCER RESEARCH, 2018, 78 (13)
  • [5] Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia
    M R Janes
    C Vu
    S Mallya
    M P Shieh
    J J Limon
    L-S Li
    K A Jessen
    M B Martin
    P Ren
    M B Lilly
    L S Sender
    Y Liu
    C Rommel
    D A Fruman
    Leukemia, 2013, 27 : 586 - 594
  • [6] Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia
    Janes, M. R.
    Vu, C.
    Mallya, S.
    Shieh, M. P.
    Limon, J. J.
    Li, L-S
    Jessen, K. A.
    Martin, M. B.
    Ren, P.
    Lilly, M. B.
    Sender, L. S.
    Liu, Y.
    Rommel, C.
    Fruman, D. A.
    LEUKEMIA, 2013, 27 (03) : 586 - 594
  • [7] Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant
    Hsu, Pei-Yin
    Wu, Victoria Shang
    Kanaya, Noriko
    Petrossian, Karineh
    Hsu, Hang-Kai
    Duc Nguyen
    Schmolze, Daniel
    Kai, Masaya
    Liu, Chun-Yu
    Lu, Hannah
    Chu, Peiguo
    Vito, Courtney A.
    Kruper, Laura
    Mortimer, Joanne
    Chen, Shiuan
    CLINICAL CANCER RESEARCH, 2018, 24 (02) : 395 - 406
  • [8] MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma
    Slotkin, Emily K.
    Patwardhan, Parag P.
    Vasudeva, Shyamprasad D.
    de Stanchina, Elisa
    Tap, William D.
    Schwartz, Gary K.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (02) : 395 - 406
  • [9] A Novel Quinoline Based Second-generation mTOR Inhibitor that Induces Apoptosis and Disrupts PI3K-Akt-mTOR Signaling in Human Leukemia HL-60 Cells
    Kumar, Suresh
    Guru, Santosh Kumar
    Venkateswarlu, Vunnam
    Malik, Fayaz
    Vishwakarma, Ram A.
    Sawant, Sanghapal D.
    Bhushan, Shashi
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2015, 15 (10) : 1297 - 1304
  • [10] Synergistic anti-cancer activity of cyclin-dependent kinase 4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing triple negative breast cancer
    Yamamoto, T.
    Kanaya, N.
    Somlo, G.
    Chen, S.
    CANCER RESEARCH, 2019, 79 (04)
12